Remarkably long-lasting tachyphylaxis of pain responses to ET-1: evidence against central nervous system involvement.
A profound tachyphylaxis of the acute nocifensive flinching (pain) response to subcutaneous injection of endothelin-1 (ET-1) into the hind paw footpad is shown by the reduced response to a second injection. Flinching from the second injection was 20% +/- 5%, 57% +/- 18%, 79% +/- 35%, and 100% +/- 17% of that from the first injection (both 200 micromol/L, 2 nmol) at respective intervals of 24, 30, 48, and 72 h. Inhibition of afferent impulses by local anesthesia of the sciatic nerve, reducing initial flinching to 6%-13% of control, did not affect the tachyphylaxis for the second injection at 24 h. There was no cross-desensitization between formalin and ET-1 injected sequentially into the same paw. Suppression of descending inhibitory effects from endogenous opiates by naloxone (5-8 mg/kg, i.p.), given 30 min before the second ET-1 injection, did not prevent tachyphylaxis. Diffuse effects caused by an initial subcutaneous ET-1 injection into the tail or forepaw resulted in sensitization of the response to ET-1 in the hind paw, rather than tachyphylaxis. In contrast, selective inhibition of local ETA receptors during the initial administration of ET-1, by the antagonist BQ-123 (3.2 mmol/L), reduced tachyphylaxis of nocifensive flinching. Therefore, prolonged pain tachyphylaxis is not due to reduced responsiveness of the CNS, but rather depends on the functional sensitivity or availability of peripheral ET(A) receptors.
Khodorova
Alla
A
Department of Anesthesiology, Perioperative and Pain Medicine, Pain Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115-6110, USA.
Strichartz
Gary R
GR
D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D002490:Central Nervous System / Q000502:physiology*; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1 / Q000008:administration & dosage / Q000494:pharmacology*; D005528:Foot / Q000294:innervation; D005557:Formaldehyde / Q000008:administration & dosage / Q000494:pharmacology; D006614:Hindlimb / Q000187:drug effects / Q000294:innervation; D006930:Hyperalgesia / Q000139:chemically induced; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced*; D010147:Pain Measurement; D010456:Peptides, Cyclic / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects; D013618:Tachyphylaxis / Q000502:physiology*; D013997:Time Factors; D014110:Touch
D000777:Anesthetics; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D010456:Peptides, Cyclic; D005557:Formaldehyde; D009270:Naloxone; C072247:cyclo(Trp-Asp-Pro-Val-Leu)